Antimuscarinics have remained the standard of care for patients with overactive bladder (OAB) syndrome for several decades, despite the fact that, owing to their adverse effects, these drugs are ...
Sept. 20, 2005 (Atlanta) — Results from the STAR trial, comparing two new-generation antimuscarinics solifenacin and tolterodine extended release (ER), suggest that solifenacin is superior in reducing ...
Studies comparing propiverine hydrochloride with newer antimuscarinic agents such as solifenacin succinate for the treatment of overactive bladder (OAB) in Japanese patients have not been performed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results